Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of “Buy” by Analysts

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has been assigned an average rating of “Buy” from the ten brokerages that are covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $9.31.

TRVI has been the topic of a number of research reports. Leerink Partners started coverage on Trevi Therapeutics in a report on Monday, September 9th. They set an “outperform” rating and a $7.00 price target on the stock. B. Riley reiterated a “buy” rating and issued a $6.00 target price on shares of Trevi Therapeutics in a research note on Monday, October 7th. Leerink Partnrs upgraded Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. D. Boral Capital reiterated a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research report on Thursday, December 12th. Finally, HC Wainwright upped their price objective on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a research report on Thursday, December 12th.

Trevi Therapeutics Stock Up 0.5 %

TRVI opened at $4.12 on Thursday. Trevi Therapeutics has a 52 week low of $1.27 and a 52 week high of $4.68. The business’s 50 day moving average is $3.25 and its two-hundred day moving average is $3.07. The firm has a market cap of $316.69 million, a price-to-earnings ratio of -9.36 and a beta of 0.96.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter in the previous year, the firm posted ($0.08) EPS. Equities analysts expect that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Trading of Trevi Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in TRVI. BNP Paribas Financial Markets increased its holdings in Trevi Therapeutics by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after buying an additional 6,764 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in shares of Trevi Therapeutics in the 2nd quarter worth approximately $61,000. Intech Investment Management LLC purchased a new position in Trevi Therapeutics in the 3rd quarter valued at approximately $63,000. The Manufacturers Life Insurance Company raised its holdings in Trevi Therapeutics by 87.6% during the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after purchasing an additional 11,450 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Trevi Therapeutics during the third quarter worth $78,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.